# ReiThera

Rome-based viral-vector CDMO built by the Okairos founding team after GSK's 2014 acquisition of Okairos; GMP development and manufacture of adenoviral (GRAd), MVA and AAV vectors for genetic vaccines and advanced therapies.


Source: https://en.bioecon.ru/companies/reithera/
Updated: 2026-09-18

- Country: Italy

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Founded | 2014 — continued by the Okairos founding team after GSK acquired Okairos | https://www.reithera.com/company/about-us/ |
| Headquarters | Rome, Italy (Via di Castel Romano 100) | https://www.reithera.com/ |
| Production site | GMP site in Rome with six independent GMP suites (3,470 m2) for clinical-grade ATMP production | https://www.reithera.com/ |
| Capacity | Up to 2,000 L bioreactor capacity and 3,500 vials per batch fill-finish | https://www.reithera.com/ |
| Partnership | Validated its ChAd/GRAd adenoviral platforms with GSK and in large COVID-19 vaccine trials | https://www.reithera.com/company/about-us/, https://www.nature.com/articles/d43978-021-00089-4 |

Independent sources: nature.com

## Technologies

- [Adenoviral vector gene therapy](https://en.bioecon.ru/technology/adenoviral-vector-gene-therapy/)